EP Patent

EP2765988A1 — Ocular composition containing bromfenac with increased bioavailability

Assigned to Bausch and Lomb Inc · Expires 2014-08-20 · 12y expired

What this patent protects

Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient c…

USPTO Abstract

Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAY™ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.

Drugs covered by this patent

Patent Metadata

Patent number
EP2765988A1
Jurisdiction
EP
Classification
—
Expires
2014-08-20
Drug substance claim
No
Drug product claim
No
Assignee
Bausch and Lomb Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.